ALPHA PRO TECH, LTD. ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS

ALPHA PRO TECH LTD (APT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ALPHA PRO TECH, LTD. ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS Second Quarter Net Sales Increased by 12% to $18.7 Million from $16.7 Million in the Second Quarter of 2025; Second Quarter Net Income Increased by 47% to $1.8 Million from $1.2 Million in the Prior

Original reporting
Published Aug 6, 2026, 2:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 2:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$APT
Bullish
medium confidence
Mentioned
$APT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$APTBullishMed
01

Why it matters

Traders can update near-term expectations using the reported sales, net income, gross margin, and the explicit note that IEEPA tariff refunds reduced cost of goods sold; forward risk hinges on whether additional refunds are received and when.

02

Market read

A primary-source earnings release with quantified quarterly growth and a clearly identified tariff-refund swing factor, plus balance-sheet context (cash, no debt).

03

What to watch

Management highlights ongoing litigation and uncertain timing for additional tariff recoveries, which can create earnings estimate dispersion even if current quarter beats.

Relevance 7/10Novelty 7/10Timing: filed Aug 6, 2026, Q2 2026 results released same day

Background

The 8-K (Item 2.02) includes Exhibit 99.1 with Alpha Pro Tech’s Q2 2026 financial results and management commentary on segment performance, housing-market conditions, and IEEPA tariff refund litigation.

Company-level read

Ticker impact

$APTBullishMedium confidence
Context

Alpha Pro Tech reports Q2 2026 net sales of $18.7M (+12%) and net income of $1.8M (+47%), plus cash $18.9M and no debt as of June 30, 2026.

Expected impact

Likely modest positive bias, but with volatility risk around the timing and outcome of additional IEEPA tariff refunds.

Evidence & confidence

The filing provides concrete quarterly financials, margin impact from the IEEPA tariff refund, and management commentary on housing weakness and ongoing litigation uncertainty, which can drive revisions to forward estimates.

Market effects

Read-through to building products and disposable protective apparel demand, with tariff pass-through and refund litigation as a key swing factor.

No specific regional demand shock beyond U.S. housing starts commentary.

International channel partner strength is cited, but the filing does not quantify cross-border exposure beyond segment sales.

Counterpoint

The headline profit growth is partly boosted by IEEPA tariff refund effects; excluding it, growth is smaller and margins are less favorable.

Key entities

  • Alpha Pro Tech, Ltd.

    NYSE American-listed company reporting Q2 2026 results and discussing IEEPA tariff refund impacts and ongoing litigation uncertainty.

  • IEEPA tariff refund

    Refund recognized in the quarter that positively impacted gross profit and net income; additional refunds remain uncertain pending litigation.

Related articles

$APTMed

ALPHA PRO TECH, LTD. ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS

ALPHA PRO TECH LTD (APT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ALPHA PRO TECH, LTD. ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS Third Quarter Net Sales Increased by 12.3% to $16.6 Million, from $14.8 Million for the Third Quarter of 2025 Third Quarter Net Income Increased by 97.2% to $1.9 Million from $1.0 Million in the Prio

$CPIXMedAI 8/10

Cumberland Pharmaceuticals Q3 Earnings Call Highlights

Cumberland Pharmaceuticals (CPIX) reported Q3 earnings, including a $108M net funding estimate from a transaction, a $1.50 special dividend, and share repurchase plans. The company projects cash to fund operations for over five years. Cumberland is preparing a new drug application for ifetroban to treat Duchenne muscular dystrophy, with FDA rolling review granted. The company also discussed other clinical programs and retained majority ownership of Cumberland Emerging Technologies.

$GOHighAI 8/10

What Grocery Outlet (GO) Said on Its Q3 Earnings Call

Grocery Outlet (GO) reported Q3 adjusted earnings of $0.16 per share, down from $0.21 a year earlier, with adjusted EBITDA falling to $59.4 million. The company cited promotional spending, higher supply chain costs, and increased produce shrink for the decline. GO forecasted Q4 comparable-store sales growth of 1.5% to 2.5% and adjusted earnings of $0.11 to $0.14 per share. The company plans to open 20-31 net new stores in 2027, all in existing markets.

$CAPRLow

Capricor Therapeutics Q3 Earnings Call Highlights

Capricor Therapeutics reported a Q3 net loss of $42.7M, widening from $24.6M a year earlier. The company highlighted positive data on Deramiocel, its lead therapy, showing improved upper limb function in patients. Capricor is preparing for a potential launch while resolving a distribution dispute with Nippon Shinyaku. The company has sufficient cash to fund operations for at least 12 months.